BACKGROUND: Survival of scleroderma has changed since the renal crisis treatment has become possible. AIMS: To document the changes in survival and organ system causes of mortality in systemic sclerosis (SSc) over the past 25 years in patients from a single medical centre. METHODS: Consecutive patients evaluated at the University of Pittsburgh, Pittsburgh, Pennsylvania, USA between 1 January 1972 and 31 December 1996 were studied. Survival was determined in five 5-year time periods between 1972 and 1997. Causes of death included scleroderma-related (scleroderma renal crisis, pulmonary arterial hypertension, pulmonary fibrosis (PF), gastrointestinal (GI), heart and multiorgan failure) and non-scleroderma-related (cancer, atherosclerotic cardiovascular or cerebrovascular disease, infection, sudden death, other and unknown) causes. RESULTS: The 10-year survival improved steadily from 54% to 66% during each of the time intervals. There was a significant improvement in survival for patients during 1982-91 compared with those during 1972-81 (p<0.001), even when patients with renal crisis were excluded (p<0.005). The frequency of deaths due to renal crisis significantly decreased over the 30-year time period, from 42% to 6% of scleroderma-related deaths (p<0.001), whereas the proportion of patients with scleroderma who died of PF increased from 6% to 33% (p<0.001). The frequency of pulmonary hypertension, independent of PF, also significantly increased during this time period (p<0.05). There were no changes in scleroderma GI- and heart-related deaths, nor in any of the non-scleroderma-related causes, although patients with scleroderma were less likely to die from scleroderma-related problems in the past 15 years. CONCLUSION: The change in the pattern of scleroderma-related deaths over the past 30 years demonstrates that the lung (both pulmonary hypertension and PF) is the primary cause of scleroderma-related deaths today. It is important that aggressive searches continue to develop better therapies for these severe pulmonary complications of SSc.
BACKGROUND: Survival of scleroderma has changed since the renal crisis treatment has become possible. AIMS: To document the changes in survival and organ system causes of mortality in systemic sclerosis (SSc) over the past 25 years in patients from a single medical centre. METHODS: Consecutive patients evaluated at the University of Pittsburgh, Pittsburgh, Pennsylvania, USA between 1 January 1972 and 31 December 1996 were studied. Survival was determined in five 5-year time periods between 1972 and 1997. Causes of death included scleroderma-related (scleroderma renal crisis, pulmonary arterial hypertension, pulmonary fibrosis (PF), gastrointestinal (GI), heart and multiorgan failure) and non-scleroderma-related (cancer, atherosclerotic cardiovascular or cerebrovascular disease, infection, sudden death, other and unknown) causes. RESULTS: The 10-year survival improved steadily from 54% to 66% during each of the time intervals. There was a significant improvement in survival for patients during 1982-91 compared with those during 1972-81 (p<0.001), even when patients with renal crisis were excluded (p<0.005). The frequency of deaths due to renal crisis significantly decreased over the 30-year time period, from 42% to 6% of scleroderma-related deaths (p<0.001), whereas the proportion of patients with scleroderma who died of PF increased from 6% to 33% (p<0.001). The frequency of pulmonary hypertension, independent of PF, also significantly increased during this time period (p<0.05). There were no changes in scleroderma GI- and heart-related deaths, nor in any of the non-scleroderma-related causes, although patients with scleroderma were less likely to die from scleroderma-related problems in the past 15 years. CONCLUSION: The change in the pattern of scleroderma-related deaths over the past 30 years demonstrates that the lung (both pulmonary hypertension and PF) is the primary cause of scleroderma-related deaths today. It is important that aggressive searches continue to develop better therapies for these severe pulmonary complications of SSc.
Authors: K J Bulpitt; P J Clements; P A Lachenbruch; H E Paulus; J B Peter; M S Agopian; J Z Singer; V D Steen; D O Clegg; C M Ziminski; G S Alarcon; M E Luggen; R P Polisson; R F Willkens; J C Reading; H J Williams; J R Ward Journal: Ann Intern Med Date: 1993-04-15 Impact factor: 25.391
Authors: Elizabeth Schulman; Kun Chen; Gregory Saboeiro; Abraham Sanders; Kyriakos Kirou; Robert F Spiera; Anne R Bass; Doruk Erkan Journal: HSS J Date: 2010-10-26
Authors: Sangmee Bae; Rajeev Saggar; Marcy B Bolster; Lorinda Chung; Mary Ellen Csuka; Chris Derk; Robyn Domsic; Aryeh Fischer; Tracy Frech; Avram Goldberg; Monique Hinchcliff; Vivien Hsu; Laura Hummers; Elena Schiopu; Maureen D Mayes; Vallerie McLaughlin; Jerry Molitor; Nausheen Naz; Daniel E Furst; Paul Maranian; Virginia Steen; Dinesh Khanna Journal: Ann Rheum Dis Date: 2012-02-02 Impact factor: 19.103
Authors: Lorinda Chung; Juliana Liu; Lori Parsons; Paul M Hassoun; Michael McGoon; David B Badesch; Dave P Miller; Mark R Nicolls; Roham T Zamanian Journal: Chest Date: 2010-05-27 Impact factor: 9.410
Authors: Li Gao; Mary J Emond; Tin Louie; Chris Cheadle; Alan E Berger; Nicholas Rafaels; Candelaria Vergara; Yoonhee Kim; Margaret A Taub; Ingo Ruczinski; Stephen C Mathai; Stephen S Rich; Deborah A Nickerson; Laura K Hummers; Michael J Bamshad; Paul M Hassoun; Rasika A Mathias; Kathleen C Barnes Journal: Arthritis Rheumatol Date: 2016-01 Impact factor: 10.995
Authors: Matthew R Lammi; Stephen C Mathai; Lesley Ann Saketkoo; Robyn T Domsic; Christine Bojanowski; Daniel E Furst; Virginia D Steen Journal: Arthritis Rheumatol Date: 2016-03 Impact factor: 10.995